Investing.com - Recursion Pharmaceuticals (NASDAQ: RXRX) reported fourth quarter EPS of $-0.42, $0.04 better than the analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results